In experimental setups involving guinea pig ureter-afferent nerve and mouse bladder-pelvic nerve, RO-3 has been observed to lower afferent nerve activity that is prompted by distension or α,β-meATP in a dose-responsive manner^[1].

Moreover, RO-3 demonstrates efficacy across several rodent pain models and in cystometry analyses designed to assess various aspects of the sensory oversight of the urination reflex^[1].

RO-3 also exhibits moderate to high metabolic endurance in rat and human liver cells and microsomes, alongside high permeability and oral bioavailability (14%). In rats, it has a moderately brief in vivo plasma half-life (t1/2=0.41 hours)^[1].